文献速递糖尿病

1型糖尿病进展风险因素的年龄依赖性效应特征分析

Characterising the age-dependent effects of risk factors on type 1 diabetes progression.
PubMed 文献 · Diabetologia · 2022-01-18

基于TrialNet Pathway to Prevention研究中1至45岁自身抗体阳性高危个体的纵向数据,采用灵活样条模型分析关键风险预测因素随年龄变化的效应。单抗体阳性者(n=4893)分析进展至多抗体或1型糖尿病,多抗体阳性者(n=3856)分析进展至1型糖尿病。多种人口学、免疫和代谢预测因素呈现显著的年龄依赖性效应。

要点

  • 单抗体阳性者中HLA-DR3、GAD65抗体阳性、BMI升高和HOMA-IR的效应随年龄增加而增强。
  • 单抗体阳性者中胰岛素自身抗体阳性的效应随年龄增长而减弱。
  • 预测风险评分Index60在较年轻年龄时风险估计更佳,而DPTRS未见年龄依赖性效应。

核心结论

  • 分析疾病预测因素的年龄依赖性效应可增进对1型糖尿病进展的理解和预测,应据此优化预测模型并指导机制研究。

研究设计与样本

  • 利用TrialNet Pathway to Prevention研究中1至45岁招募的单抗体或多抗体阳性高危个体的纵向数据,采用灵活样条模型评估关键预测因素的年龄变化效应。
  • 单抗体阳性参与者(n=4893)分析进展至多抗体或1型糖尿病。
  • 多抗体阳性参与者(n=3856)分析进展至1型糖尿病。

主要发现

  • 单抗体阳性者中,HLA-DR3(p=0.007)、GAD65自身抗体阳性(p=0.008)、BMI升高(p=0.007)和HOMA-IR(p=0.002)对疾病进展的效应随年龄增加而显著增强。
  • 单抗体阳性者中,胰岛素自身抗体阳性的效应随年龄增长而减弱(p<0.001)。
  • 多抗体阳性者中,男性与进展风险增加相关(p=0.002),HLA DR3/4的效应随年龄增长而减弱(p=0.05)。
  • 单抗体和多抗体阳性者中,多种胰岛功能指标的HR随年龄变化显著。
  • 预测风险评分Index60在较年轻年龄时风险估计更佳(单抗体p=0.007,多抗体p<0.001);DPTRS未见年龄依赖性效应(p=0.861和p=0.178)。

关键数值与推荐

  • 单抗体阳性者中HLA-DR3、GAD65自身抗体阳性、BMI升高和HOMA-IR的效应随年龄增加而显著增强。
  • 单抗体阳性者中胰岛素自身抗体阳性的效应随年龄增长而减弱(p<0.001)。
  • 多抗体阳性者中男性与进展风险增加相关(p=0.002),HLA DR3/4的效应随年龄增长而减弱(p=0.05)。
  • Index60在较年轻年龄时风险估计更佳(单抗体p=0.007,多抗体p<0.001);DPTRS未见年龄依赖性效应(p=0.861和p=0.178)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Age is known to be one of the most important stratifiers of disease progression in type 1 diabetes. However, what drives the difference in rate of progression between adults and children is poorly understood. Evidence suggests that many type 1 diabetes disease predictors do not have the same effect across the age spectrum. Without a comprehensive analysis describing the varying risk profiles of predictors over the age continuum, researchers and clinicians are susceptible to inappropriate assessment of risk when examining populations of differing ages. We aimed to systematically assess and characterise how the effect of key type 1 diabetes risk predictors changes with age. METHODS: Using longitudinal data from single- and multiple-autoantibody-positive at-risk individuals recruited between the ages of 1 and 45 years in TrialNet's Pathway to Prevention Study, we assessed and visually characterised the age-varying effect of key demographic, immune and metabolic predictors of type 1 diabetes by employing a flexible spline model. Two progression outcomes were defined: participants with single autoantibodies (n=4893) were analysed for progression to multiple autoantibodies or type 1 diabetes, and participants with multiple autoantibodies were analysed (n=3856) for progression to type 1 diabetes. RESULTS: Several predictors exhibited significant age-varying effects on disease progression. Amongst single-autoantibody participants, HLA-DR3 (p=0.007), GAD65 autoantibody positivity (p=0.008), elevated BMI (p=0.007) and HOMA-IR (p=0.002) showed a significant increase in effect on disease progression with increasing age. Insulin autoantibody positivity had a diminishing effect with older age in single-autoantibody-positive participants (p<0.001). Amongst multiple-autoantibody-positive participants, male sex (p=0.002) was associated with an increase in risk for progression, and HLA DR3/4 (p=0.05) showed a decreased effect on disease progression with older age. In both single- and multiple-autoantibody-positive individuals, significant changes in HR with age were seen for multiple measures of islet function. Risk estimation using prediction risk score Index60 was found to be better at a younger age for both single- and multiple-autoantibody-positive individuals (p=0.007 and p<0.001, respectively). No age-varying effect was seen for prediction risk score DPTRS (p=0.861 and p=0.178, respectively). Multivariable analyses suggested that incorporating the age-varying effect of the individual components of these validated risk scores has the potential to enhance the risk estimate. CONCLUSIONS/INTERPRETATION: Analysing the age-varying effect of disease predictors improves understanding and prediction of type 1 diabetes disease progression, and should be leveraged to refine prediction models and guide mechanistic studies.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. So M, O'Rourke C, Ylescupidez A, et al. Characterising the age-dependent effects of risk factors on type 1 diabetes progression. Diabetologia. 2022. PMID: 35041021. doi:10.1007/s00125-021-05647-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。